Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18689367 | 0.85 | TDP1 (0.48) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL8083294 | 0.84 | TDP1 (0.44) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL14044868 | 0.83 | MEN1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL27429142 | 0.83 | TDP1 (0.50) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL959018 | 0.83 | TDP1 (0.50) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL8295860 | 0.82 | MAOA (0.51) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL18902256 | 0.82 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22416651 | 0.82 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL13273476 | 0.82 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL14822612 | 0.82 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410311-B2 | Resin composition and multilayered structure using same | KURARAY CO., LTD. (JP) | 2025-09-09 | — | — | US | disclosed |
| WO-2022268229-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | 和径医药科技（上海）有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220041850-A1 | Resin Composition and Multilayered Structure Using Same | KURARAY CO., LTD. (JP) | 2022-02-10 | — | — | US | disclosed |
| WO-2021229152-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2021-11-18 | — | — | WO | disclosed |
| US-10039761-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180208579-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-07-26 | — | — | US | disclosed |
| US-20180193341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-07-12 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
| US-20100003419-A1 | METHOD OF PRODUCING A SHAPED ARTICLE HAVING EXCELLENT BARRIER PROPERTIES | KURARAY CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100003437-A1 | METHOD OF PRODUCING A SHAPED ARTICLE HAVING EXCELLENT BARRIER PROPERTIES | KURARAY CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1817287-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | Eli Lilly and Company (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1166892-B1 | A method of producing a shaped article having excellent barrier properties | KURARAY CO (JP) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006057845-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20050233086-A1 | Method of producing a shaped article having excellent barrier properties | KURARAY CO., LTD (JP) | 2005-10-20 | — | — | US | disclosed |
| US-20040076780-A1 | Method of producing a shaped article having excellent barrier properties | KURARAY CO. LTD (JP) | 2004-04-22 | — | — | US | disclosed |
| US-20020172788-A1 | Method of producing a shaped article having excellent barrier properties | KURARAY CO., LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| EP-1166892-A2 | A method of producing a shaped article having excellent barrier properties | Kuraray Co., Ltd. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TDP1 11/4885MAOA 3428/4885MAOB 2973/4885 |
| US-10039761-B2 | Co-crystals and pharmaceutical compositions comprising the same | SUCNR1, SDHA, SDHB | TDP1 4438/4885MAOA 1124/4885MAOB 1830/4885 |
| US-20180193341-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TDP1 11/4885MAOA 3428/4885MAOB 2973/4885 |
| US-20180208579-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | TDP1 11/4885MAOA 3428/4885MAOB 2973/4885 |
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | TFPI, F2, F11 | TDP1 612/4885MAOA 282/4885MAOB 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.